StreetInsider.com News Articles

Serina Therapeutics enrolls first patient in phase 1b trial for SER-252

Thu, 19 Feb 2026 06:00:24 -0500

Serina Therapeutics Inc. (NYSE American: SER) announced the enrollment of the first patient in its Phase 1b registrational trial evaluating SER-252 for advanced Parkinson's disease, according to a company statement.

The clinical-stage biotechnology company enrolled the patient in Australia as part of a global registrational study. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson's disease whose symptoms are inadequately controlled by current standard-of-care therapies.

The company remains on track to initiate dosing during the first quarter of 2026, consistent with previously disclosed guidance. Serina has established an operational presence in

Serina Therapeutics enrolls first patient in phase 1b trial for SER-252

Thu, 19 Feb 2026 06:00:24 -0500

The company remains on track to initiate dosing during the first quarter of 2026, consistent with previously disclosed guidance. Serina has established an operational presence in

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Thu, 19 Feb 2026 06:00:00 -0500

- First patient successfully enrolled in global registrational study in Australia
- Operational presence in Australia positions Serina to advance enrollment in Cohort 1
- Company remains on track for first patient dosing in the first quarter of 2026

HUNTSVILLE, AL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, today announced that the first patient has been enrolled in the Company's Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease.

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Thu, 19 Feb 2026 06:00:00 -0500

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Thu, 19 Feb 2026 06:00:00 -0500

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Thu, 19 Feb 2026 06:00:00 -0500

Form 4 Serina Therapeutics, For: Feb 03 Filed by: Moreadith Randall

Tue, 17 Feb 2026 08:36:00 -0500

si-local-file:///var/storage/secattach/20260217/26007174.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: Moreadith Randall

Tue, 17 Feb 2026 08:36:00 -0500

si-local-file:///var/storage/secattach/20260217/26007174.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: Tenjarla Srini

Tue, 17 Feb 2026 08:29:00 -0500

si-local-file:///var/storage/secattach/20260217/26006941.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: Tenjarla Srini

Tue, 17 Feb 2026 08:29:00 -0500

si-local-file:///var/storage/secattach/20260217/26006941.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: GILL SIMBA

Tue, 17 Feb 2026 08:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26006898.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: GILL SIMBA

Tue, 17 Feb 2026 08:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26006898.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: GILL SIMBA

Tue, 17 Feb 2026 08:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26006900.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: GILL SIMBA

Tue, 17 Feb 2026 08:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26006900.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: LEDGER STEVEN A

Tue, 17 Feb 2026 08:20:00 -0500

si-local-file:///var/storage/secattach/20260217/26006857.html

Form 4 Serina Therapeutics, For: Feb 03 Filed by: LEDGER STEVEN A

Tue, 17 Feb 2026 08:20:00 -0500

si-local-file:///var/storage/secattach/20260217/26006857.html

Form EFFECT Serina Therapeutics,

Tue, 17 Feb 2026 06:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26005187.html

Form EFFECT Serina Therapeutics,

Tue, 17 Feb 2026 06:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26005187.html

Form 4 Serina Therapeutics, For: Feb 02 Filed by: Moreadith Randall

Tue, 03 Feb 2026 12:36:00 -0500

si-local-file:///var/storage/secattach/20260203/25937039.html

Form 4 Serina Therapeutics, For: Feb 02 Filed by: Moreadith Randall

Tue, 03 Feb 2026 12:36:00 -0500

si-local-file:///var/storage/secattach/20260203/25937039.html

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

Tue, 03 Feb 2026 06:00:00 -0500

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"

Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026

Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector
Meet with Serina’s CEO Steven Ledger
Register at New-FDA-Era.TribePublic.com

HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina’s CEO, Steven

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

Tue, 03 Feb 2026 06:00:00 -0500

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"

Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026

Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector
Meet with Serina’s CEO Steven Ledger
Register at New-FDA-Era.TribePublic.com

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

Tue, 03 Feb 2026 06:00:00 -0500

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"

Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026

Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector
Meet with Serina’s CEO Steven Ledger
Register at New-FDA-Era.TribePublic.com

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

Tue, 03 Feb 2026 06:00:00 -0500

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"

Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026

Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector
Meet with Serina’s CEO Steven Ledger
Register at New-FDA-Era.TribePublic.com

Form S-3 Serina Therapeutics,

Fri, 30 Jan 2026 17:19:00 -0500

si-local-file:///var/storage/secattach/20260130/25924659.html